Cerimon Pharmaceuticals, Inc. Names Timothy J. McBride As Senior Vice President Of Business Development
SOUTH SAN FRANCISCO, Calif., Sept. 28 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc. announced today Timothy J. McBride, a 24-year veteran of the pharmaceutical and biotechnology industries, has joined the Company as Senior Vice President of Business Development. Mr. McBride will report to Paul Sekhri, President and CEO, and will be responsible for managing the Company's efforts to find and secure new strategic business opportunities and product acquisitions.
Mr. McBride brings considerable experience leading business development and other operating functions in the biotechnology and pharmaceutical industries. Before joining Cerimon, Mr. McBride held senior management positions at AGY Therapeutics, Inc., a research stage biotechnology company focused on CNS disease, most recently serving as President and CEO. During Mr. McBride's tenure at AGY, he led corporate restructuring and successfully monetized the Company's major assets. Previously, Mr. McBride was Chief Business Officer at Acologix, Inc., and was a senior manager at Axys Pharmaceuticals, participating in its acquisition by Celera, Inc. Earlier in his career; Mr. McBride held transactions and commercial management roles at ALZA Corporation and AstraZeneca.
Mr. McBride holds a Bachelor of Arts degree in Economics from Bucknell University and a Masters of Business Administration degree in Marketing from Saint Mary's College.
"Tim McBride's proven track record as an incisive leader in business development in the life sciences sector will be a valuable asset to this Company," commented Mr. Sekhri. "We are extremely pleased to have Tim join us as a member of our senior management team and believe he will greatly contribute to our efforts of building a pipeline of products that is aligned with our corporate strategy."
About Cerimon Pharmaceuticals
Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for the physician who specializes in autoimmune disease, inflammation, and pain. The Company employs a corporate strategy of in-licensing clinical-stage or marketed drugs to reduce the development and regulatory risk, decrease time to market, and expand the commercial potential of known drugs. The Company currently has two drugs in development, a topical formulation of diclofenac sodium for the treatment of osteoarthritis pain and Simulect for moderate-to-severe steroid- refractory ulcerative colitis. Cerimon is well financed, having secured a $70 million Series A financing in late 2005 with the premier investors MPM, Nomura Phase 4 Ventures, and OrbiMed Advisors.
For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.
Cerimon Pharmaceuticals, Inc.CONTACT: Jim Welch, Chief Financial Officer of Cerimon Pharmaceuticals,+1-650-827-4000, jwelch@cerimon.com; or Media: Justin Jackson,jjackson@burnsmc.com, Jason Farber, jfarber@burnsmc.com; or Investors:Juliane Snowden-Andrew, jsnowden-andrew@burnsmc.com, Laura Siino,lsiino@burnsmc.com, +1-212-213-0006, all of Burns McClellan, Inc., all forCerimon Pharmaceuticals
Web site: http://www.cerimon.com/